Coeptis Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing
The PennZone/10282485

Trending...
WEXFORD, Pa., Sept. 19, 2024 ~ Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) has recently received a notification letter from the Nasdaq Hearings Panel (the "Panel") granting its request for continued listing on The Nasdaq Stock Market ("Nasdaq") through January 15, 2025. This decision is subject to the Company demonstrating compliance with Nasdaq Listing Rule 5550(a)(2).

The biopharmaceutical company, known for developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, had previously disclosed on January 29, 2024 that it had received a letter from the Listing Qualifications Staff of Nasdaq. The letter indicated that the Company was not in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing as set forth in Nasdaq Listing Rule 5550(a)(2). This was based on the closing bid price of the Company's common stock for the last 30 consecutive business days.

In response to this notice, Coeptis was given a compliance period of 180 calendar days from the date of the Original Notice to regain compliance with the Minimum Bid Price Requirement. This period was set to end on July 29, 2024, pursuant to Nasdaq Listing Rule 5810(c)(3)(A).

However, on September 12th, Coeptis presented a plan before the Panel outlining its strategy to address the minimum bid price requirement. This included their intention to implement a reverse stock split. The Panel reviewed and considered this plan and ultimately issued its decision on September 17th granting an extension.

More on The PennZone
"We are pleased with the decision from Nasdaq to grant us our extension," stated Dave Mehalick President and Chief Executive Officer of Coeptis. "We look forward to regaining and maintaining compliance with Nasdaq's continued listing requirements and continuing to focus on our goal of improving patient outcomes."

Coeptis Therapeutics Holdings, Inc., along with its subsidiaries Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., is a biopharmaceutical company that is dedicated to developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases. Their goal is to disrupt conventional treatment paradigms and improve patient outcomes. The Company's product portfolio and rights include assets licensed from Deverra Therapeutics, such as an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage unmodified natural killer cell therapy technology.

In addition to these assets, Coeptis is also developing a universal multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), as well as the GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and leading medical researchers at the Karolinska Institutet. The Company's business model focuses on maximizing the value of its current product portfolio and rights through in-license agreements, out-license agreements, co-development relationships, and strategic partnerships. These efforts are specifically targeted towards cancer and infectious diseases.

More on The PennZone
Coeptis Therapeutics Holdings, Inc. is headquartered in Wexford, PA. For more information on Coeptis and their innovative developments in the field of cell therapy, please visit their website at https://coeptistx.com/.

Cautionary Note Regarding Forward-Looking Statements:

This article may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include but are not limited to: the Company's ability to regain compliance with Nasdaq's continued listing requirements; the success of their cell therapy platforms in disrupting conventional treatment paradigms; their ability to enter into strategic partnerships and expand their product rights and offerings; and the success of their current product portfolio. These forward-looking statements speak only as of the date hereof. Coeptis Therapeutics Holdings, Inc. disclaims any obligation to update these forward-looking statements except as required by law.
Filed Under: Business
Show All News | Report Violation

0 Comments

Latest on The PennZone